// App-Quantinova.ai

: Rituximab in the Treatment of Refractory Heparin Induced Thrombocytopenia

Researchers

Presenter

  • Akshee Batra

Principal Investigators

  • Rohit Singh

  • Aneesh Singal

  • Jacqueline N. Poston

Medical Centers

  • Division of Hematology/Oncology, Department of Medicine, Larner College of Medicine at The University of Vermont, Burlington, VT

  • University of Vermont Medical Center, Burlington, VT

  • Transfusion Medicine, Division of Clinical Pathology, Department of Pathology, Larner College of Medicine at The University of Vermont, Burlington, VT

  • University of Vermont Larner College of Medicine, Burlington, VT

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Cardiovascular (CVS)

  • Pulmonary/Respiratory Diseases

Disease

  • Disseminated intravascular coagulation

  • Myocardial infarction

  • Thrombocytopenia

  • Angina

  • Venous thrombosis

Biomarkers

  • N-Acylethanolamine acid amidase

  • Platelet Factor 4

Drug/Treatment

  • Methylprednisolone

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Bivalirudin

  • Argatroban

  • Prednisone

  • Rituximab

  • Evithrom

  • Heparin

  • IVIG

Outcome

  • N/A

Study Design

  • Efficacy

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved